The purpose of this study is to determine whether a longer duration, controlled, sustained release dexamethasone delivery system would be more effective in helping patients with osteoarthritis reduce their pain, remain functional, and delay their need for knee replacement.
The objectives of the study are to assess the dexamethasone delivery system for: * Safety and tolerability * Efficacy Formal statistical analysis to compare treatment groups will not be performed due to the small number of participants in this pilot study. Summary statistics will be assessed using the short form of the knee injury and osteoarthritis outcome score (KOOS JR) surveys and questionnaires to assess pain intensity, pain medication consumption and wound assessment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
6
Sustained delivery system containing 5.0 mg of dexamethasone programmed to release an estimated 10 μg per day
Hospital for Special Surgery
New York, New York, United States
Incidence of treatment emergent adverse events
Time frame: Through 24 weeks
Change from baseline in weekly mean of the pain intensity score
Using a numeric rating scale for pain with a scale of 0 (no pain) to 10 (worst pain imaginable) at rest, during activity, and at night
Time frame: Weeks 12, 24
Change from baseline in weekly mean of the pain intensity score
Using a numeric rating scale for pain with a scale of 0 (no pain) to 10 (worst pain imaginable) at rest, during activity, and at night
Time frame: Weekly through 24 weeks
Time of onset of pain relief
Time frame: Weekly through 24 weeks
Change from baseline in KOOS-JR score (stiffness)
Using a response scale of none, mild, moderate, severe, and extreme
Time frame: Over 1, 2, 4, 8, 12, 24 weeks post treatment
Change from baseline in KOOS-JR score (pain)
Using a response scale of none, mild, moderate, severe, and extreme
Time frame: Over 1, 2, 4, 8, 12, 24 weeks post treatment
Change from baseline in KOOS-JR score (function)
Using a response scale of none, mild, moderate, severe, and extreme
Time frame: Over 1, 2, 4, 8, 12, 24 weeks post treatment
Change in patient's global impression of scores assessed via office visits
Using a numeric rating scale for pain with a scale of 0 (no pain) to 10 (worst pain imaginable)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Weeks 4, 12, 24
Change in clinical observer's global impression of scores assessed via office visits
Using a numeric rating scale for pain with a scale of 0 (no pain) to 10 (worst pain imaginable)
Time frame: Weeks 4, 12, 24
Percent of responders (defined as patients with high improvement in pain or function) according to OMERACT-OARSI criteria
Time frame: Weeks 1, 2, 4, 8, 12, 24
Average weekly consumption of rescue medications
Time frame: Through 24 weeks
Average total consumption of rescue medications
Time frame: Through 24 weeks